AR107290A1 - ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS - Google Patents
ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOSInfo
- Publication number
- AR107290A1 AR107290A1 ARP170100014A ARP170100014A AR107290A1 AR 107290 A1 AR107290 A1 AR 107290A1 AR P170100014 A ARP170100014 A AR P170100014A AR P170100014 A ARP170100014 A AR P170100014A AR 107290 A1 AR107290 A1 AR 107290A1
- Authority
- AR
- Argentina
- Prior art keywords
- n3pglu
- clinical
- seq
- amiloid
- same
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas que comprende tales anticuerpos Ab N3pGlu, y métodos para usar tales anticuerpos Ab N3pGlu para el tratamiento de una enfermedad caracterizada por deposición de Ab que incluye Enfermedad de Alzheimer clínica o pre-clínica, Síndrome de Down, y angiopatía amiloide cerebral clínica o pre-clínica. Reivindicación 1: Un anticuerpo que une Ab N3pGlu humano, caracterizado porque comprende una región variable de cadena ligera (LCVR) que tiene la secuencia de aminoácido de SEQ ID Nº 9 o SEQ ID Nº 10, y una región variable de cadena pesada (HCVR) que tiene la secuencia de aminoácido de SEQ ID Nº 8.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662279268P | 2016-01-15 | 2016-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107290A1 true AR107290A1 (es) | 2018-04-18 |
Family
ID=57966094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100014A AR107290A1 (es) | 2016-01-15 | 2017-01-04 | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS |
Country Status (17)
Country | Link |
---|---|
US (1) | US9944696B2 (es) |
EP (1) | EP3402817B1 (es) |
JP (1) | JP6634158B2 (es) |
KR (1) | KR102141969B1 (es) |
CN (2) | CN114891100B (es) |
AR (1) | AR107290A1 (es) |
AU (1) | AU2017207250B2 (es) |
BR (1) | BR112018011308A2 (es) |
CA (1) | CA3007000C (es) |
EA (1) | EA037784B1 (es) |
ES (1) | ES2968255T3 (es) |
IL (1) | IL259748B2 (es) |
JO (1) | JOP20170004B1 (es) |
MX (1) | MX2018008557A (es) |
TW (1) | TWI634126B (es) |
WO (1) | WO2017123517A1 (es) |
ZA (1) | ZA201901207B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白-β之抗體及其用途 |
JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
EP3946603A1 (en) | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica NV | Antibodies to pyroglutamate amyloid-ss and uses thereof |
MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
JP2024503025A (ja) | 2021-01-11 | 2024-01-24 | イーライ リリー アンド カンパニー | 抗N3pGluアミロイドベータ抗体及びその使用 |
TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
CA3236504A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
AU2022376930A1 (en) | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
AR127484A1 (es) | 2021-10-29 | 2024-01-31 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
KR20240099347A (ko) | 2021-10-29 | 2024-06-28 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
AP2007003890A0 (en) | 2004-07-30 | 2007-02-28 | Rinat Neuroscience Corp | Antibodies directed against amy-loid-beta peptide and methods using same |
MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
RU2011100127A (ru) | 2008-06-12 | 2012-07-20 | Аффирис Аг (At) | Соединение, содержащее пептид, для лечения симптомов болезни паркинсона |
JP2011527338A (ja) | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | 神経新生を促進する方法 |
CN102131519B (zh) * | 2008-07-21 | 2016-01-13 | 前体生物药物股份公司 | 诊断抗体测定 |
EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
EP3042917B1 (en) * | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
AU2014233615B2 (en) * | 2010-08-12 | 2016-08-11 | Eli Lilly And Company | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
-
2017
- 2017-01-03 JO JOP/2017/0004A patent/JOP20170004B1/ar active
- 2017-01-04 AR ARP170100014A patent/AR107290A1/es active IP Right Grant
- 2017-01-04 TW TW106100110A patent/TWI634126B/zh active
- 2017-01-10 KR KR1020187019854A patent/KR102141969B1/ko active IP Right Grant
- 2017-01-10 CA CA3007000A patent/CA3007000C/en active Active
- 2017-01-10 ES ES17703491T patent/ES2968255T3/es active Active
- 2017-01-10 BR BR112018011308A patent/BR112018011308A2/pt unknown
- 2017-01-10 JP JP2018529131A patent/JP6634158B2/ja active Active
- 2017-01-10 AU AU2017207250A patent/AU2017207250B2/en active Active
- 2017-01-10 EA EA201891286A patent/EA037784B1/ru unknown
- 2017-01-10 CN CN202210627760.XA patent/CN114891100B/zh active Active
- 2017-01-10 EP EP17703491.5A patent/EP3402817B1/en active Active
- 2017-01-10 CN CN201780006700.3A patent/CN108473566B/zh active Active
- 2017-01-10 US US15/402,268 patent/US9944696B2/en active Active
- 2017-01-10 WO PCT/US2017/012795 patent/WO2017123517A1/en active Application Filing
- 2017-01-10 MX MX2018008557A patent/MX2018008557A/es unknown
- 2017-01-10 IL IL259748A patent/IL259748B2/en unknown
-
2019
- 2019-02-26 ZA ZA2019/01207A patent/ZA201901207B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI634126B (zh) | 2018-09-01 |
CN108473566A (zh) | 2018-08-31 |
MX2018008557A (es) | 2018-09-18 |
IL259748B (en) | 2022-11-01 |
KR102141969B1 (ko) | 2020-08-06 |
IL259748B2 (en) | 2023-03-01 |
EP3402817B1 (en) | 2023-10-18 |
CN114891100A (zh) | 2022-08-12 |
BR112018011308A2 (pt) | 2018-11-27 |
EP3402817A1 (en) | 2018-11-21 |
EA037784B1 (ru) | 2021-05-20 |
JP6634158B2 (ja) | 2020-01-22 |
EA201891286A1 (ru) | 2018-12-28 |
KR20180086268A (ko) | 2018-07-30 |
US9944696B2 (en) | 2018-04-17 |
ZA201901207B (en) | 2022-05-25 |
CN108473566B (zh) | 2022-06-17 |
JOP20170004B1 (ar) | 2022-09-15 |
AU2017207250B2 (en) | 2019-04-18 |
WO2017123517A1 (en) | 2017-07-20 |
AU2017207250A1 (en) | 2018-06-07 |
JP2019507107A (ja) | 2019-03-14 |
ES2968255T3 (es) | 2024-05-08 |
CN114891100B (zh) | 2024-05-03 |
TW201739761A (zh) | 2017-11-16 |
CA3007000C (en) | 2021-07-27 |
US20170204171A1 (en) | 2017-07-20 |
IL259748A (en) | 2018-07-31 |
CA3007000A1 (en) | 2017-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
CL2016003346A1 (es) | Anticuerpos anti-tau humanizados | |
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
CO2019004186A2 (es) | Inmunoglobulinas y usos de estas | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
AR109715A1 (es) | Anticuerpos anti-cd27 | |
CO2018000809A2 (es) | Anticuerpos para cd40 | |
DOP2017000031A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
PE20161390A1 (es) | Anticuerpos multiespecificos | |
PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
PE20181176A1 (es) | Composiciones biofarmaceuticas | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
UY36820A (es) | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh | |
UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |